Possible Drug-drug Interactions Among Elderly Patients Receiving Antiviral Therapy for Chronic Hepatitis B

Overview

Journal Croat Med J

Specialty General Medicine

Date 2024 Sep 2

PMID 39219194

Authors

Mehmet Celik

Yusuf Arslan

Taylan Onder

Sevil Alkan

Ahmet Sahin

Fethiye Akgul

Affiliations

Soon will be listed here.

Abstract

Aim: To identify possible drug-drug interactions in patients taking medications for other comorbidities while on antiviral therapy for chronic hepatitis B.

Methods: The study enrolled patients with chronic hepatitis B aged ≥60 years who were treated with antiviral therapy in five hospitals in Turkey between January 1 and March 1, 2023. The Lexicomp® Drug Interactions program was used to identify possible drug-drug interactions.

Results: The study included 213 patients (119 [55.9%] men). The mean age was 68.5 years. A potential drug-drug interaction was identified in 112 patients (52.6%). The most common type of interaction was type C ("follow the treatment") (71.54%). The number of potential drug-drug interactions increased with an increase in the number of drugs used by the patients. A robust and affirmative correlation was observed between the number of medications used and the number of possible drug-drug interactions (r=0.791, P<0.001). Adverse interactions (interactions of types C and D, 3.7% of cases) were limited to patients receiving tenofovir disoproxil fumarate.

Conclusion: Nonsteroidal anti-inflammatory medications should be used cautiously in elderly patients with chronic hepatitis B treated with tenofovir disoproxil fumarate due to the increased risk of renal toxicity.

References

Matthews S . Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006; 28(2):184-203. DOI: 10.1016/j.clinthera.2006.02.012. View

Milton J, Hill-Smith I, Jackson S . Prescribing for older people. BMJ. 2008; 336(7644):606-9. PMC: 2267940. DOI: 10.1136/bmj.39503.424653.80. View

Bhagavathula A, Berhanie A, Tigistu H, Abraham Y, Getachew Y, Khan T . Prevalence of potential drug-drug interactions among internal medicine ward in University of Gondar Teaching Hospital, Ethiopia. Asian Pac J Trop Biomed. 2014; 4(Suppl 1):S204-8. PMC: 4025339. DOI: 10.12980/APJTB.4.2014C1172. View

Roade L, Riveiro-Barciela M, Esteban R, Buti M . Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis. 2021; 8:2049936120985954. PMC: 7871062. DOI: 10.1177/2049936120985954. View

Carnovale C, Dassano A, Mosini G, Mazhar F, DAddio F, Pozzi M . The β-cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review. Acta Diabetol. 2019; 57(2):117-131. DOI: 10.1007/s00592-019-01370-1. View

Seto W, Lo Y, Pawlotsky J, Yuen M . Chronic hepatitis B virus infection. Lancet. 2018; 392(10161):2313-2324. DOI: 10.1016/S0140-6736(18)31865-8. View

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey G . What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1):230. PMC: 5635569. DOI: 10.1186/s12877-017-0621-2. View

Mousavi S, Ghanbari G . Potential drug-drug interactions among hospitalized patients in a developing country. Caspian J Intern Med. 2017; 8(4):282-288. PMC: 5686307. DOI: 10.22088/cjim.8.4.282. View

Jeng W, Papatheodoridis G, Lok A . Hepatitis B. Lancet. 2023; 401(10381):1039-1052. DOI: 10.1016/S0140-6736(22)01468-4. View

10.

Bickel M, Khaykin P, Stephan C, Schmidt K, Buettner M, Amann K . Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med. 2013; 14(10):633-8. DOI: 10.1111/hiv.12072. View

11.

Marcellin P, Wong D, Sievert W, Buggisch P, Petersen J, Flisiak R . Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019; 39(10):1868-1875. DOI: 10.1111/liv.14155. View

12.

Amioka K, Kuzuya T, Kushihara H, Ejiri M, Nitta A, Nabeshima T . Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. J Pharm Pharmacol. 2007; 59(10):1383-7. DOI: 10.1211/jpp.59.10.0008. View

13.

Chien R, Liaw Y . Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses. 2022; 14(2). PMC: 8877417. DOI: 10.3390/v14020434. View

14.

Kearney B, Flaherty J, Shah J . Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43(9):595-612. DOI: 10.2165/00003088-200443090-00003. View

15.

Fitzmaurice M, Wong A, Akerberg H, Avramovska S, Smithburger P, Buckley M . Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. Drug Saf. 2019; 42(9):1035-1044. DOI: 10.1007/s40264-019-00829-y. View

16.

Ahn J, Lee H, Lim J, Pan C, Nguyen M, Kim W . Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther. 2015; 43(1):134-44. PMC: 4926997. DOI: 10.1111/apt.13440. View

17.

Bushardt R, Massey E, Simpson T, Ariail J, Simpson K . Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008; 3(2):383-9. PMC: 2546482. DOI: 10.2147/cia.s2468. View

18.

Maher R, Hanlon J, Hajjar E . Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2013; 13(1):57-65. PMC: 3864987. DOI: 10.1517/14740338.2013.827660. View

19.

Kheshti R, Aalipour M, Namazi S . A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016; 5(4):257-263. PMC: 5084483. DOI: 10.4103/2279-042X.192461. View

20.

Tan M, Bhadoria A, Cui F, Tan A, Holten J, Easterbrook P . Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 6(2):106-119. PMC: 7801814. DOI: 10.1016/S2468-1253(20)30307-1. View